Abstract
The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is one of the most potent prosurvival signaling cascades that is aberrantly activated in a variety of human cancers. Recent evidence demonstrates that pathological activation of Akt also frequently occurs in neuroblastoma and correlates with poor prognosis. Thus, therapeutic targeting of PI3K/Akt/mTOR may present a promising approach for the design of molecular targeted therapies in neuroblastoma. Several strategies have in recent years been developed to interfere with distinct components of PI3K/Akt/mTOR signaling at different levels of the cascade. It will be subject to future studies to evaluate which of these compounds are most suitable for the treatment of neuroblastoma. Eventually, PI3K/Akt/mTOR targeting agents may open novel perspectives to improve the poor prognosis of patients with neuroblastoma especially in advanced stages of the disease.
Current Cancer Drug Targets
Title: The PI3K/Akt/mTOR Pathway as Therapeutic Target in Neuroblastoma
Volume: 9 Issue: 6
Author(s): S. Fulda
Affiliation:
Keywords: Neuroblastoma, PI3K, Akt, mTOR, apoptosis, cancer
Abstract: The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is one of the most potent prosurvival signaling cascades that is aberrantly activated in a variety of human cancers. Recent evidence demonstrates that pathological activation of Akt also frequently occurs in neuroblastoma and correlates with poor prognosis. Thus, therapeutic targeting of PI3K/Akt/mTOR may present a promising approach for the design of molecular targeted therapies in neuroblastoma. Several strategies have in recent years been developed to interfere with distinct components of PI3K/Akt/mTOR signaling at different levels of the cascade. It will be subject to future studies to evaluate which of these compounds are most suitable for the treatment of neuroblastoma. Eventually, PI3K/Akt/mTOR targeting agents may open novel perspectives to improve the poor prognosis of patients with neuroblastoma especially in advanced stages of the disease.
Export Options
About this article
Cite this article as:
Fulda S., The PI3K/Akt/mTOR Pathway as Therapeutic Target in Neuroblastoma, Current Cancer Drug Targets 2009; 9 (6) . https://dx.doi.org/10.2174/156800909789271521
DOI https://dx.doi.org/10.2174/156800909789271521 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacological Applications of Lignins and Lignins Related Compounds: An Overview
Current Organic Chemistry Anti-Angiogenic Therapies for Children with Cancer
Current Cancer Drug Targets Synthesis and Cholinesterase Inhibitory Activity of N-Phosphorylated/ N-Tiophosphorylated Tacrine
Medicinal Chemistry Control of β-Site Amyloid Precursor Protein-Cleaving Enzyme-1 Expression by Protein Kinase C-λ/ι and Nuclear Factor κ-B
Current Alzheimer Research Ras-Induced Resistance to Lapatinib is Overcome by MEK Inhibition
Current Cancer Drug Targets Transferrin and the Transferrin Receptor: Of Magic Bullets and Other Concerns
Inflammation & Allergy - Drug Targets (Discontinued) Gene Expression Analysis Approach to Establish Possible Links Between Parkinson's Disease, Cancer and Cardiovascular Diseases
CNS & Neurological Disorders - Drug Targets Imatinib Reduces the Vasculogenic Potential of Plastic Tumor Cells
Current Angiogenesis (Discontinued) Safety of Nanoparticles in Medicine
Current Drug Targets Microdissection and the Study of Cancer Pathways
Current Molecular Medicine Mediterranean Diet and Dementia of the Alzheimer Type
Current Aging Science Methylenetetrahydrofolate Reductase (MTHFR): A Novel Target for Cancer Therapy
Current Pharmaceutical Design Glutamate mGlu5-Adenosine A2A-Dopamine D2 Receptor Interactions in the Striatum. Implications for Drug Therapy in Neuro-psychiatric Disorders and Drug Abuse
Current Medicinal Chemistry - Central Nervous System Agents The Role of the PACAP Signaling System in Depression
Current Pharmaceutical Design Critical Enzymes Involved in Endocannabinoid Metabolism
Protein & Peptide Letters From Bortezomib to other Inhibitors of the Proteasome and Beyond
Current Pharmaceutical Design Modulation of Amyloid β Peptide1-42 Cytotoxicity and Aggregation in Vitro by Glucose and Chondroitin Sulfate
Current Alzheimer Research Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications
Current Cancer Drug Targets Cerebral Arachidonate Cascade in Dementia: Alzheimers Disease and Vascular Dementia
Current Neuropharmacology Cytopathological Mechanisms in Mitochondrial Disease
Current Chemical Biology